Group 1 - The core viewpoint of the news is the performance and holdings of the Wanjiay Economic New Momentum Mixed C Fund, which has shown a decline in recent value but positive returns over longer periods [1] - As of May 23, 2025, the latest net value of the fund is 1.6007 yuan, reflecting a decrease of 1.79% [1] - The fund's one-month return is -4.46%, ranking 4362 out of 4480 in its category, while its six-month return is 22.90%, ranking 161 out of 4322, and its year-to-date return is 28.00%, ranking 90 out of 4372 [1] Group 2 - The top ten stock holdings of the Wanjiay Economic New Momentum Mixed C Fund account for a total of 75.95%, with significant positions in companies such as Ruixin Micro (9.12%), BeiGene-U (8.80%), and Deepin Technology (8.64%) [1] - The fund was established on February 7, 2018, and as of March 31, 2025, it has a total scale of 1.223 billion yuan [1] - The fund manager, Huang Xingliang, has a strong academic background with a Ph.D. from Tsinghua University and extensive experience in the investment management industry [2]

证券代码：688114 证券简称：华大智造 公告编号：2025-031 深圳华大智造科技股份有限公司 截至本公告披露日，韦炜先生直接持有公司股份 83,400 股，并通过西藏家 华创业投资合伙企业（有限合伙）间接持有公司股票。离任后，韦炜先生将继续 遵守《上市公司董事和高级管理人员所持本公司股份及其变动管理规则》《上市 公司股东减持股份管理暂行办法》《上海证券交易所科创板股票上市规则》《上 海证券交易所上市公司自律监管指引第 15 号——股东及董事、高级管理人员减 持股份》等相关规定。 特此公告。 深圳华大智造科技股份有限公司 | | | | | | | | 是否继 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | | 是否存 | | | | | | | | | | | 续在上 | | | | | | | | 原定任 | | | | | 具体职 | 在未履 | | | | | 离任时 | | | | 离任原 | | 市公司 | | | | 姓名 | 离任职务 | | | | 期 ...

证券代码：688114 证券简称：华大智造 公告编号：2025-031 姓名 离任职务 离任时 间 原定任 期到期 日 离任原 因 是否继 续在上 市公司 及其控 股子公 司任职 具体职 务（如 适用） 是否存 在未履 行完毕 的公开 承诺 韦炜 高级副总 裁、董事会 秘书 2025 年 5 月 21 日 2026 年 9 月 19 日 个人原 因 是 法务 否 一、提前离任的基本情况 韦炜先生自 2020 年担任公司高级副总裁兼董事会秘书以来，勤勉尽责，恪 尽职守，在完善公司治理结构和机制、信息披露、投资者关系管理等方面发挥了 重要作用，公司及董事会对于韦炜先生在任职期间为公司发展所做出的重要贡献 表示衷心感谢和诚挚敬意。 截至本公告披露日，韦炜先生直接持有公司股份 83,400 股，并通过西藏家 华创业投资合伙企业（有限合伙）间接持有公司股票。离任后，韦炜先生将继续 遵守《上市公司董事和高级管理人员所持本公司股份及其变动管理规则》《上市 公司股东减持股份管理暂行办法》《上海证券交易所科创板股票上市规则》《上 海证券交易所上市公司自律监管指引第 15 号——股东及董事、高级管理人员减 持股份》等相关规定。 ...

Core Insights - A new microbial species named "Niallia tiangongensis" has been discovered in the Chinese space station, marking a significant advancement in understanding microbial diversity in space [1][2][3] Group 1: Discovery and Significance - The discovery of Niallia tiangongensis expands knowledge of microbial diversity in extreme space environments, showcasing China's capabilities in space exploration [1][2] - The research was published in the International Journal of Systematic and Evolutionary Microbiology, highlighting its scientific importance [2] Group 2: Research Methodology - The research utilized the DNBSEQ-T7 sequencing platform developed by BGI Genomics, which is capable of generating at least 7Tb of data in 24 hours, demonstrating advanced technological capabilities [1][2] - Samples were collected by astronauts during the Shenzhou 15 mission in May 2023, using sterile wipes to gather microbial samples from various surfaces within the space station [3] Group 3: Microbial Characteristics - Niallia tiangongensis is a Gram-positive, aerobic, spore-forming rod with a genome size of 5,166,230 base pairs and a G+C content of 35.6 mol% [3][4] - The species exhibits unique traits, including the ability to hydrolyze gelatin, indicating its adaptability to nutrient-limited environments [4] Group 4: Genetic Analysis - Genomic analysis revealed significant differences between Niallia tiangongensis and its closest terrestrial relative, Niallia circulans, with only 83.3% genomic similarity, below the species definition threshold of 95% [3][4] - Key mutations in proteins associated with oxidative stress response and radiation damage repair were identified, enhancing its survival capabilities in space [4]

Core Viewpoint - The company is preparing for its 2024 Annual General Meeting (AGM) to ensure the rights of shareholders and maintain order during the meeting, with specific rules and procedures outlined for participation and voting [1][2][3]. Group 1: Meeting Procedures - The company has established necessary verification processes for attendees to confirm their eligibility to participate in the AGM [1]. - Attendees must arrive on time for registration, and latecomers will not be allowed to vote [1]. - The meeting will follow a predetermined agenda for discussing and voting on proposals [1][3]. Group 2: Shareholder Rights and Responsibilities - Shareholders and their representatives have the right to speak, inquire, and vote during the AGM, but must adhere to rules to avoid disrupting the meeting [2]. - Requests to speak must be registered in advance, and speaking time is limited to five minutes [2]. - Questions that may disclose confidential information can be refused by the meeting host [2]. Group 3: Voting Process - Attendees must express their opinions on proposals by indicating agreement, disagreement, or abstention, and must sign their ballots [3]. - Two shareholder representatives will be appointed to oversee the counting of votes, ensuring transparency [3]. - The AGM will utilize both in-person and online voting methods, with results published afterward [3][6]. Group 4: Financial Reports and Proposals - The company will present several key reports during the AGM, including the 2024 Board of Directors' Work Report, the 2024 Supervisory Board Work Report, and the 2024 Financial Settlement Report [7][8][9]. - A proposal for the 2025 Financial Budget Report will also be discussed, reflecting the company's strategic planning [9][10]. - The company plans to propose no profit distribution for 2024 due to negative net profits, while a share buyback amounting to 230.27 million yuan will be considered as part of the cash dividend [13][14]. Group 5: Operational Highlights - The company reported a net loss of 600.83 million yuan for 2024, although this represents a reduction in losses compared to the previous year [26]. - The company has achieved significant advancements in its core product lines, including a 48.59% increase in sales volume of sequencing instruments [27]. - The company is focusing on enhancing its global supply chain and has established a manufacturing base in the United States to better serve local demand [27][29]. Group 6: Future Plans - The company aims to strengthen its governance structure and improve market value management in 2025 [30]. - Plans include enhancing investor relations and continuing to expand its international presence [30]. - The company will focus on maintaining compliance with regulations and improving operational efficiency [30].

证券代码：688114 证券简称：华大智造 公告编号：2025-030 深圳华大智造科技股份有限公司 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 一、 召开会议的基本情况 （一） 股东大会类型和届次 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票 相结合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 6 月 9 日 15 点 00 分 召开地点：深圳市盐田区梅沙街道云华路 9 号华大时空中心 C 区国际会议 中心 419 会议室 （五） 网络投票的系统、起止日期和投票时间。 ? 股东大会召开日期：2025年6月9日 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 6 月 9 日 至2025 年 6 月 9 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15- ...

深圳华大智造科技股份有限公司 2024 年年度股东大会 会议资料 2025 年 6 月 1 | . | . | | | | --- | --- | --- | --- | | | . | | | | | V | | | | | 4 . | | 1 | | 2024 | 年年度股东大会会议须知 3 | | | --- | --- | --- | | 2024 | 年年度股东大会会议议程 5 | | | 2024 | 年年度股东大会会议议案 7 | | | 《关于〈公司 | 2024 年度董事会工作报告〉的议案》 7 | | | 《关于〈公司 | 年度监事会工作报告〉的议案》 8 2024 | | | 《关于〈公司 | 2024 年度财务决算报告〉的议案》 9 | | | 《关于〈公司 | 年度财务预算报告〉的议案》 10 2025 | | | 《关于〈公司 | 2024 年年度报告〉及其摘要的议案》 | 11 | | 《关于公司 2024 | 年度利润分配预案的议案》 12 | | | | 《关于未弥补亏损达实收股本总额三分之一的议案》 13 | | | 《关于续聘公司 | 年度财务报告及内部控制审计机构的议案 ...

证券代码：688114 证券简称：华大智造 公告编号：2025-030 深圳华大智造科技股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2024年年度股东大会 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票 相结合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 6 月 9 日 15 点 00 分 召开地点：深圳市盐田区梅沙街道云华路 9 号华大时空中心 C 区国际会议 中心 419 会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 6 月 9 日 至2025 年 6 月 9 日 不涉及 二、 会议审议事项 本次股东大会审议议案及投票股东类型 | 序号 | | 议案名称 | 投票股东类型 | | --- | --- | --- | --- | ...

Core Insights - Synthetic biology is at a pivotal growth point in China, attracting significant attention from global investors due to its unique innovation potential and broad application prospects [1] - The Chinese synthetic biology market comprises 116 listed companies, including technology platform providers, CXO companies offering biosynthesis solutions, and chemical and pharmaceutical companies seeking transformation [1] - The industry showcases a mix of established players with decades of experience and newly founded companies, highlighting the vast development potential and imagination space behind synthetic biology [1] Industry Overview - Enabling technology companies in synthetic biology are experiencing rapid growth, leveraging cutting-edge technologies such as gene editing, gene synthesis, gene sequencing, big data, and machine learning [1] - Current enabling technologies are still in their early stages, with high technical barriers, leading companies to pursue collaborations with universities, research institutions, and other enterprises to advance R&D [1] Leading Companies - BGI Genomics and Berry Genomics are recognized as leaders among enabling technology companies in China's synthetic biology sector [2] - BGI Genomics focuses on gene sequencing instruments, laboratory automation, and new business areas, enhancing its global influence in precision medicine and health [3] - Berry Genomics, a leader in gene sequencing, offers services in reproductive health, genetic disease detection, and tumor detection, supported by proprietary technologies like PCR-free methods [6] Platform Companies - Synthetic biology platform companies primarily provide services related to process improvement and enzyme engineering, with few achieving the functionality of cell factories [9] - Kingfisher Biotech is a prominent global gene supplier, evolving into a leading provider of research and production services with a strong reputation in life sciences [11] - Yikole Biotech specializes in synthetic biology technology, focusing on biomanufacturing and possessing a vast library of over 20,000 enzymes [13][16] Emerging Trends - The Chinese synthetic biology sector is witnessing a surge in investment opportunities driven by policy guidance and market demand, with companies increasing their focus on technological innovation and R&D [22] - Key application areas include biopharmaceutical raw materials, bio-based materials, and the development of cell and gene therapy drugs, supported by integrated R&D and production capabilities [16][20]

Group 1 - Turkish clinical genetic testing laboratory Genoks has announced a partnership with BGI Genomics to enhance its clinical testing capabilities in the local market [1] - The collaboration involves the introduction of BGI's sequencing platform and supporting products [1] - This partnership aims to empower local public health initiatives and advance genomic research in Turkey [1]